In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-<i>faecalis</i> and Non-<i>faecium</i> Enterococcal Isolates With/Without VanC Phenotype: Clinical Implications for Infective Endocarditis
(1) Background: Alternative antibiotics are needed to treat infective endocarditis (IE) caused by non-<i>faecalis</i>/non-<i>faecium</i> enterococci; we aimed to assess the in vitro activity of ampicillin plus ceftriaxone (AMP + CTR) against these enterococci and to describe...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/12/12/2511 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846103609902628864 |
|---|---|
| author | Javier García-González María A. Cañas Guillermo Cuervo Marta Hernández-Meneses Miguel A. Verdejo Marta Bodro Javier Díez de los Ríos Oriol Gasch Alba Ribera Carles Falces Andrés Perissinotti Bárbara Vidal Eduard Quintana Asunción Moreno Maria Piquet Ignasi Roca Mariana Fernández-Pittol Sol M. San José-Villar Cristina García-de-la-Mària José M. Miró the Hospital Clínic Endocarditis Study Group |
| author_facet | Javier García-González María A. Cañas Guillermo Cuervo Marta Hernández-Meneses Miguel A. Verdejo Marta Bodro Javier Díez de los Ríos Oriol Gasch Alba Ribera Carles Falces Andrés Perissinotti Bárbara Vidal Eduard Quintana Asunción Moreno Maria Piquet Ignasi Roca Mariana Fernández-Pittol Sol M. San José-Villar Cristina García-de-la-Mària José M. Miró the Hospital Clínic Endocarditis Study Group |
| author_sort | Javier García-González |
| collection | DOAJ |
| description | (1) Background: Alternative antibiotics are needed to treat infective endocarditis (IE) caused by non-<i>faecalis</i>/non-<i>faecium</i> enterococci; we aimed to assess the in vitro activity of ampicillin plus ceftriaxone (AMP + CTR) against these enterococci and to describe its clinical efficacy in IE cases. (2) Methods: Time–kill curves with standard (ISI) and high (IHI) inocula were performed to test <i>VanC</i> isolates [3 <i>E. casseliflavus</i> (ECAS) and 1 <i>E. gallinarum</i> (EGALL)] and non-<i>VanC</i> isolates [1 <i>E. durans</i> (EDUR), 1 <i>E. hirae</i> (EHIR) and 1 <i>E. raffinosus</i> (ERAF)]. The narrative literature review of IE cases treated with AMP + CTR was analyzed alongside three study cases. Clinical outcomes were relapse and death. (3) Results: Ampicillin plus gentamicin (AMP + GEN) showed synergistic and bactericidal activity against most isolates. AMP + CTR was synergistic at ISI for EGALL, EDUR, and EHIR and bactericidal against EHIR. At IHI, indifferent activity was observed for all isolates. In IE cases treated with AMP + CTR, it was only effective for EDUR and EHIR. Clinical information for EGALL IE is lacking. For IE caused by ECAS and ERAF, AMP + CTR seems suboptimal or ineffective, respectively. (4) AMP + CTR cannot be recommended for treating IE due to ECAS/ERAF. In contrast, this combination was effective in IE caused by EDUR/EHIR and could be recommended. |
| format | Article |
| id | doaj-art-e4a63ce27f334ed4837bf8fb9f2985ce |
| institution | Kabale University |
| issn | 2076-2607 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj-art-e4a63ce27f334ed4837bf8fb9f2985ce2024-12-27T14:41:24ZengMDPI AGMicroorganisms2076-26072024-12-011212251110.3390/microorganisms12122511In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-<i>faecalis</i> and Non-<i>faecium</i> Enterococcal Isolates With/Without VanC Phenotype: Clinical Implications for Infective EndocarditisJavier García-González0María A. Cañas1Guillermo Cuervo2Marta Hernández-Meneses3Miguel A. Verdejo4Marta Bodro5Javier Díez de los Ríos6Oriol Gasch7Alba Ribera8Carles Falces9Andrés Perissinotti10Bárbara Vidal11Eduard Quintana12Asunción Moreno13Maria Piquet14Ignasi Roca15Mariana Fernández-Pittol16Sol M. San José-Villar17Cristina García-de-la-Mària18José M. Miró19the Hospital Clínic Endocarditis Study GroupExperimental Endocarditis Laboratory, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainExperimental Endocarditis Laboratory, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainInfectious Diseases Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainInfectious Diseases Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainInfectious Diseases Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainInfectious Diseases Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainDepartment of Internal Medicine, Hospital de Vic, 08500 Vic, SpainDepartment of Infectious Diseases, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08208 Sabadell, SpainDepartment of Internal Medicine, Hospital de Barcelona, 08034 Barcelona, SpainCardiology Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainNuclear Medicine Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainCardiology Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainCardiovascular Surgery Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainInfectious Diseases Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainDepartment of Microbiology, Hospital Clínic, Biomedical Diagnostic Center (CDB) and ISGlobal, University of Barcelona, 08036 Barcelona, SpainDepartment of Microbiology, Hospital Clínic, Biomedical Diagnostic Center (CDB) and ISGlobal, University of Barcelona, 08036 Barcelona, SpainDepartment of Microbiology, Hospital Clínic, Biomedical Diagnostic Center (CDB) and ISGlobal, University of Barcelona, 08036 Barcelona, SpainDepartment of Microbiology, Hospital Clínic, Biomedical Diagnostic Center (CDB) and ISGlobal, University of Barcelona, 08036 Barcelona, SpainExperimental Endocarditis Laboratory, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, SpainInfectious Diseases Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona—Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, Spain(1) Background: Alternative antibiotics are needed to treat infective endocarditis (IE) caused by non-<i>faecalis</i>/non-<i>faecium</i> enterococci; we aimed to assess the in vitro activity of ampicillin plus ceftriaxone (AMP + CTR) against these enterococci and to describe its clinical efficacy in IE cases. (2) Methods: Time–kill curves with standard (ISI) and high (IHI) inocula were performed to test <i>VanC</i> isolates [3 <i>E. casseliflavus</i> (ECAS) and 1 <i>E. gallinarum</i> (EGALL)] and non-<i>VanC</i> isolates [1 <i>E. durans</i> (EDUR), 1 <i>E. hirae</i> (EHIR) and 1 <i>E. raffinosus</i> (ERAF)]. The narrative literature review of IE cases treated with AMP + CTR was analyzed alongside three study cases. Clinical outcomes were relapse and death. (3) Results: Ampicillin plus gentamicin (AMP + GEN) showed synergistic and bactericidal activity against most isolates. AMP + CTR was synergistic at ISI for EGALL, EDUR, and EHIR and bactericidal against EHIR. At IHI, indifferent activity was observed for all isolates. In IE cases treated with AMP + CTR, it was only effective for EDUR and EHIR. Clinical information for EGALL IE is lacking. For IE caused by ECAS and ERAF, AMP + CTR seems suboptimal or ineffective, respectively. (4) AMP + CTR cannot be recommended for treating IE due to ECAS/ERAF. In contrast, this combination was effective in IE caused by EDUR/EHIR and could be recommended.https://www.mdpi.com/2076-2607/12/12/2511enterococcal endocarditisin vitro studytime–kill curvessynergy<i>E. casseliflavus</i><i>E. gallinarum</i> |
| spellingShingle | Javier García-González María A. Cañas Guillermo Cuervo Marta Hernández-Meneses Miguel A. Verdejo Marta Bodro Javier Díez de los Ríos Oriol Gasch Alba Ribera Carles Falces Andrés Perissinotti Bárbara Vidal Eduard Quintana Asunción Moreno Maria Piquet Ignasi Roca Mariana Fernández-Pittol Sol M. San José-Villar Cristina García-de-la-Mària José M. Miró the Hospital Clínic Endocarditis Study Group In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-<i>faecalis</i> and Non-<i>faecium</i> Enterococcal Isolates With/Without VanC Phenotype: Clinical Implications for Infective Endocarditis Microorganisms enterococcal endocarditis in vitro study time–kill curves synergy <i>E. casseliflavus</i> <i>E. gallinarum</i> |
| title | In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-<i>faecalis</i> and Non-<i>faecium</i> Enterococcal Isolates With/Without VanC Phenotype: Clinical Implications for Infective Endocarditis |
| title_full | In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-<i>faecalis</i> and Non-<i>faecium</i> Enterococcal Isolates With/Without VanC Phenotype: Clinical Implications for Infective Endocarditis |
| title_fullStr | In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-<i>faecalis</i> and Non-<i>faecium</i> Enterococcal Isolates With/Without VanC Phenotype: Clinical Implications for Infective Endocarditis |
| title_full_unstemmed | In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-<i>faecalis</i> and Non-<i>faecium</i> Enterococcal Isolates With/Without VanC Phenotype: Clinical Implications for Infective Endocarditis |
| title_short | In Vitro Activity of Ampicillin Plus Ceftriaxone Against Non-<i>faecalis</i> and Non-<i>faecium</i> Enterococcal Isolates With/Without VanC Phenotype: Clinical Implications for Infective Endocarditis |
| title_sort | in vitro activity of ampicillin plus ceftriaxone against non i faecalis i and non i faecium i enterococcal isolates with without vanc phenotype clinical implications for infective endocarditis |
| topic | enterococcal endocarditis in vitro study time–kill curves synergy <i>E. casseliflavus</i> <i>E. gallinarum</i> |
| url | https://www.mdpi.com/2076-2607/12/12/2511 |
| work_keys_str_mv | AT javiergarciagonzalez invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT mariaacanas invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT guillermocuervo invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT martahernandezmeneses invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT miguelaverdejo invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT martabodro invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT javierdiezdelosrios invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT oriolgasch invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT albaribera invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT carlesfalces invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT andresperissinotti invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT barbaravidal invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT eduardquintana invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT asuncionmoreno invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT mariapiquet invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT ignasiroca invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT marianafernandezpittol invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT solmsanjosevillar invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT cristinagarciadelamaria invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT josemmiro invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis AT thehospitalclinicendocarditisstudygroup invitroactivityofampicillinplusceftriaxoneagainstnonifaecalisiandnonifaeciumienterococcalisolateswithwithoutvancphenotypeclinicalimplicationsforinfectiveendocarditis |